{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:46:13Z","timestamp":1794861973146,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8247143562"],"award-info":[{"award-number":["8247143562"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["22ZR1453100"],"award-info":[{"award-number":["22ZR1453100"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Changning District Science and Technology Commission","award":["CNKW2024Y19"],"award-info":[{"award-number":["CNKW2024Y19"]}]},{"name":"Science and Technology Development project of Shanghai University of Traditional Chinese Medicine","award":["24KFL095"],"award-info":[{"award-number":["24KFL095"]}]},{"name":"Shi Qi medical master Changning studio","award":["2023"],"award-info":[{"award-number":["2023"]}]},{"name":"Training Program for High-caliber Talents of Clinical Research at Affiliated Hospital of SHUTCM","award":["2023LCRC24"],"award-info":[{"award-number":["2023LCRC24"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long non-coding RNA ITSN1-2(lncRNA ITSN1-2) promotes fibroblast-like synovicytes (FLS) proliferation and suppress apoptosis through activation of the NOD2\/RIP2 signaling pathway, thereby exacerbating synovitis in Rheumatoid arthritis (RA) pathology. Juanbi Qianggu Formula (JBQG), a clinically efficacious traditional Chinese medicine, has shown significant efficiency in inhibiting FLS activation in RA and alleviating disease progression in RA patients. However, the molecular mechanism underlying JBQG's anti-arthritic effects remains incompletely understood, particularly regarding its potential to modulate lncRNA ITSN1-2-mediated NOD2\/RIP2 signaling in FLS activation. This study aims to investigate the functional interplay between JBQG and the lncRNA ITSN1-2\/NOD2\/RIP2 axis in regulating FLS behavior during RA development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Synovial tissues were collected from 24 rheumatoid arthritis (RA) patients and 20 osteoarthritis (OA) patients to observe the lncRNA ITSN1-2\/NOD2\/RIP2 signal in RA synovial tissue and its correlation with RA inflammation and bone destruction. Blood-absorbed components of JBQG were analyzed through mass spectrometry, while network pharmacology and in vitro experiments were conducted to investigate JBQG's regulatory effects on NOD2\/RIP2 signaling. Mechanistic studies focused on lncRNA-ITSN1-2\/miR-2683-3p\/PELI3\/RIP2 interactions, employing dual-luciferase assays, FISH staining, and Co-IP\/Western blot. To evaluate therapeutic efficacy, a collagen-induced arthritis (CIA) rat model with lncRNA ITSN1-2 overexpression was established. JBQG's effects were assessed through histopathological examination and serum inflammation factors analysis following 23\u00a0g\/kg\/day treatment for 4\u00a0weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>LncRNA ITSN1-2\/NOD2\/RIP2 signaling was significantly activated in RA synovial tissues, showing profound correlation with RA disease inflammation and progression. JBQG treatment reduced cytoplasmic lncRNA ITSN1-2 levels in FLS, thereby inhibiting NOD2\/RIP2 pathway activation and FLS functions in migration and invasion. Mechanistically, lncRNA ITSN1-2 exerted competitive endogenous RNA (ceRNA) activity by sequestering miR-2683-3p, which upregulated PELI3 expression. This induction promoted RIP2 K48 ubiquitination, destabilizing RIP2 protein integrity and inhibiting downstream NF-\u03baB signaling. Consequently, FLS migratory and invasive capacities were significantly diminished, underscoring JBQG's dual regulatory impact on lncRNA-miRNA cross-talk and inflammatory cytokine cascades.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrates that JBQG exerts potent anti-arthritic effects in RA therapy through dual regulatory mechanisms targeting the lncRNA ITSN1-2\/miR-2683-3p\/PELI3\/RIP2 axis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-025-01164-4","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T23:53:40Z","timestamp":1751932420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Juanbi Qianggu Formula inhibits fibroblast-like synovicytes activation via repressing LncRNA ITSN1-2 to promote RIP2 K48 ubiquitination"],"prefix":"10.1186","volume":"20","author":[{"given":"Yanqin","family":"Bian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanshan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boran","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qigui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9305-0776","authenticated-orcid":false,"given":"Lianbo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"5","key":"1164_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00296-008-0809-z","volume":"29","author":"YJ Xiang","year":"2009","unstructured":"Xiang YJ, Dai SM. Prevalence of rheumatic diseases and disability in China. Rheumatol Int. 2009;29(5):481\u201390.","journal-title":"Rheumatol Int"},{"key":"1164_CR2","doi-asserted-by":"publisher","first-page":"1132602","DOI":"10.3389\/fphar.2023.1132602","volume":"14","author":"L Ran","year":"2023","unstructured":"Ran L, Xu B, Han HH, Wang JY, Cao BR, Meng XH, Zhang CB, Xin PF, Qiu GW, et al. The effect of JuanBiQiangGu granules in combination with methotrexate on joint inflammation in rheumatoid arthritis: a randomized controlled trial. Front Pharmacol. 2023;14:1132602.","journal-title":"Front Pharmacol"},{"issue":"18","key":"1164_CR3","first-page":"4864","volume":"48","author":"XH Meng","year":"2023","unstructured":"Meng XH, Zhong S, Han HH, Shi Q, Sun ST, Xiao LB. Effect of Juanbi Qianggu Formula on biological behaviors of fibroblast-like synoviocytes in rheumatoid arthritis by regulating FGFR1 signaling pathway based on network pharmacology and cell function experiments. Zhongguo Zhong Yao Za Zhi. 2023;48(18):4864\u201373.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"1164_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pbiomolbio.2022.09.007","volume":"175","author":"A Ravaei","year":"2022","unstructured":"Ravaei A, Zimmer-Bensch G, Govoni M, Rubini M. lncRNA-mediated synovitis in rheumatoid arthritis: a perspective for biomarker development. Prog Biophys Mol Biol. 2022;175:103\u201319.","journal-title":"Prog Biophys Mol Biol"},{"key":"1164_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106549","volume":"186","author":"J Yang","year":"2022","unstructured":"Yang J, Li Z, Wang L, Yun X, Zeng Y, Ng JPL, Lo H, Wang Y, Zhang K, Law BYK, et al. The role of non-coding RNAs (miRNA and lncRNA) in the clinical management of rheumatoid arthritis. Pharmacol Res. 2022;186: 106549.","journal-title":"Pharmacol Res"},{"issue":"10","key":"1164_CR6","first-page":"10451","volume":"10","author":"X Gong","year":"2017","unstructured":"Gong X, Fan X, Zhang Z, Cai Q, Guo M, Gao C, Xiao L, Yue T. Circulating lnc-ITSN1-2 expression presents a high value in diagnosis of rheumatoid arthritis and correlates with disease activity. Int J Clin Exp Pathol. 2017;10(10):10451\u20138.","journal-title":"Int J Clin Exp Pathol"},{"issue":"8","key":"1164_CR7","first-page":"4650","volume":"11","author":"T Yue","year":"2019","unstructured":"Yue T, Fan X, Zhang Z, Liu Z, Guo M, Bai F, Gong X, Gao C, Xiao L. Downregulation of lncRNA ITSN1-2 correlates with decreased disease risk and activity of rheumatoid arthritis (RA), and reduces RA fibroblast-like synoviocytes proliferation and inflammation via inhibiting NOD2\/RIP2 signaling pathway. Am J Transl Res. 2019;11(8):4650\u201366.","journal-title":"Am J Transl Res"},{"issue":"3","key":"1164_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3899\/jrheum.200286","volume":"48","author":"J Grosse","year":"2021","unstructured":"Grosse J, Allado E, Albuisson E, Pierreisnard A, Couderc M, Chary-Valckenaere I, Loeuille D. Evaluation of bone erosions in rheumatoid arthritis: the ultrasound score for erosions versus the modified sharp\/van der Heijde score for erosions. J Rheumatol. 2021;48(3):335\u20138.","journal-title":"J Rheumatol"},{"key":"1164_CR9","doi-asserted-by":"publisher","first-page":"605616","DOI":"10.3389\/fimmu.2021.605616","volume":"12","author":"X Zhou","year":"2021","unstructured":"Zhou X, Xie D, Huang J, Lu A, Wang R, Jin Y, Zhang R, Chang C, Xu L, Xu L, et al. Therapeutic effects of (5R)-5-hydroxytriptolide on fibroblast-like synoviocytes in rheumatoid arthritis via lncRNA WAKMAR2\/miR-4478\/E2F1\/p53 Axis. Front Immunol. 2021;12:605616.","journal-title":"Front Immunol"},{"key":"1164_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/art.42674","volume":"76","author":"X Meng","year":"2023","unstructured":"Meng X, Chen Z, Li T, Nie Z, Han H, Zhong S, Yin Z, Sun S, Xie J, Shen J, et al. Role and therapeutic potential for targeting fibroblast growth factor 10\/FGFR1 in relapsed Rheumatoid Arthritis. Arthritis Rheumatol. 2023;76:32\u201347.","journal-title":"Arthritis Rheumatol"},{"key":"1164_CR11","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3389\/fimmu.2020.00852","volume":"11","author":"J Nie","year":"2020","unstructured":"Nie J, Zhao Q. Lnc-ITSN1-2, derived from RNA sequencing, correlates with increased disease risk, activity and promotes CD4(+) T cell activation, proliferation and Th1\/Th17 cell differentiation by serving as a ceRNA for IL-23R via sponging mir-125a in inflammatory bowel disease. Front Immunol. 2020;11:852.","journal-title":"Front Immunol"},{"issue":"6","key":"1164_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24468","volume":"36","author":"G Wang","year":"2022","unstructured":"Wang G, Zhou Y, Zhong T, Song A, Xue Q. Longitudinal variation of circulating Inc-ITSN1-2: a novel biomarker reflecting disease severity, inflammation, recurrence, and death risk in acute ischemic stroke patients. J Clin Lab Anal. 2022;36(6): e24468.","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"1164_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22836","volume":"33","author":"Q Zeng","year":"2019","unstructured":"Zeng Q, Wu J, Yang S. Circulating lncRNA ITSN1-2 is upregulated, and its high expression correlates with increased disease severity, elevated inflammation, and poor survival in sepsis patients. J Clin Lab Anal. 2019;33(4): e22836.","journal-title":"J Clin Lab Anal"},{"issue":"9","key":"1164_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/ni.2669","volume":"14","author":"S Yang","year":"2013","unstructured":"Yang S, Wang B, Humphries F, Jackson R, Healy ME, Bergin R, Aviello G, Hall B, McNamara D, Darby T, et al. Pellino3 ubiquitinates RIP2 and mediates Nod2-induced signaling and protective effects in colitis. Nat Immunol. 2013;14(9):927\u201336.","journal-title":"Nat Immunol"},{"issue":"4","key":"1164_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24330","volume":"36","author":"Q Huang","year":"2022","unstructured":"Huang Q, Wang Y, He F. Blood long non-coding RNA intersectin 1\u20132 is highly expressed and links with increased Th17 cells, inflammation, multiple organ dysfunction, and mortality risk in sepsis patients. J Clin Lab Anal. 2022;36(4): e24330.","journal-title":"J Clin Lab Anal"},{"issue":"2","key":"1164_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23053","volume":"34","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Niu C. The correlation of long non-coding RNA intersectin 1\u20132 with disease risk, disease severity, inflammation, and prognosis of acute ischemic stroke. J Clin Lab Anal. 2020;34(2): e23053.","journal-title":"J Clin Lab Anal"},{"issue":"5","key":"1164_CR17","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s10787-021-00854-3","volume":"29","author":"M Li","year":"2021","unstructured":"Li M, Zhou X. Long noncoding RNA intersectin 1\u20132 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis. Inflammopharmacology. 2021;29(5):1371\u20138.","journal-title":"Inflammopharmacology"},{"issue":"5","key":"1164_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23170","volume":"34","author":"J Li","year":"2020","unstructured":"Li J, Bu X, Chen X, Xiong P, Chen Z, Yu L. Predictive value of long non-coding RNA intersectin 1\u20132 for occurrence and in-hospital mortality of severe acute pancreatitis. J Clin Lab Anal. 2020;34(5): e23170.","journal-title":"J Clin Lab Anal"},{"key":"1164_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112218","volume":"134","author":"HM Li","year":"2024","unstructured":"Li HM, Wang LJ, Wang YP, Li XM, Pan HF. Differences in the expression of long noncoding RNAs in peripheral blood mononuclear cells indicate potential biomarkers for rheumatoid arthritis. Int Immunopharmacol. 2024;134: 112218.","journal-title":"Int Immunopharmacol"},{"key":"1164_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110128","volume":"118","author":"W Zhao","year":"2023","unstructured":"Zhao W, Leng RX, Ye DQ. RIPK2 as a promising druggable target for autoimmune diseases. Int Immunopharmacol. 2023;118: 110128.","journal-title":"Int Immunopharmacol"},{"key":"1164_CR21","doi-asserted-by":"publisher","first-page":"1127722","DOI":"10.3389\/fphar.2023.1127722","volume":"14","author":"AT Pham","year":"2023","unstructured":"Pham AT, Ghilardi AF, Sun L. Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases. Front Pharmacol. 2023;14:1127722.","journal-title":"Front Pharmacol"},{"key":"1164_CR22","doi-asserted-by":"publisher","first-page":"1192970","DOI":"10.3389\/fphar.2023.1192970","volume":"14","author":"J You","year":"2023","unstructured":"You J, Wang Y, Chen H, Jin F. RIPK2: a promising target for cancer treatment. Front Pharmacol. 2023;14:1192970.","journal-title":"Front Pharmacol"},{"key":"1164_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115683","volume":"259","author":"E Tian","year":"2023","unstructured":"Tian E, Zhou C, Quan S, Su C, Zhang G, Yu Q, Li J, Zhang J. RIPK2 inhibitors for disease therapy: current status and perspectives. Eur J Med Chem. 2023;259: 115683.","journal-title":"Eur J Med Chem"},{"issue":"4","key":"1164_CR24","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.4049\/jimmunol.178.4.2380","volume":"178","author":"JH Park","year":"2007","unstructured":"Park JH, Kim YG, McDonald C, Kanneganti TD, Hasegawa M, Body-Malapel M, Inohara N, Nunez G. RICK\/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J Immunol. 2007;178(4):2380\u20136.","journal-title":"J Immunol"},{"issue":"1","key":"1164_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12974-023-02968-7","volume":"20","author":"S Zheng","year":"2023","unstructured":"Zheng S, Li Y, Song X, Wu M, Yu L, Huang G, Liu T, Zhang L, Shang M, Zhu Q, et al. OTUD1 ameliorates cerebral ischemic injury through inhibiting inflammation by disrupting K63-linked deubiquitination of RIP2. J Neuroinflammation. 2023;20(1):281.","journal-title":"J Neuroinflammation"},{"issue":"7","key":"1164_CR26","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/cdd.2017.33","volume":"24","author":"A Witt","year":"2017","unstructured":"Witt A, Vucic D. Diverse ubiquitin linkages regulate RIP kinases-mediated inflammatory and cell death signaling. Cell Death Differ. 2017;24(7):1160\u201371.","journal-title":"Cell Death Differ"},{"issue":"1","key":"1164_CR27","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1038\/s41467-018-07016-0","volume":"9","author":"S Panda","year":"2018","unstructured":"Panda S, Gekara NO. The deubiquitinase MYSM1 dampens NOD2-mediated inflammation and tissue damage by inactivating the RIP2 complex. Nat Commun. 2018;9(1):4654.","journal-title":"Nat Commun"},{"key":"1164_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108648","volume":"223","author":"SR Hofmann","year":"2021","unstructured":"Hofmann SR, Girschick L, Stein R, Schulze F. Immune modulating effects of receptor interacting protein 2 (RIP2) in autoinflammation and immunity. Clin Immunol. 2021;223: 108648.","journal-title":"Clin Immunol"},{"issue":"5","key":"1164_CR29","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1093\/nar\/gks1471","volume":"41","author":"PV Nazarov","year":"2013","unstructured":"Nazarov PV, Reinsbach SE, Muller A, Nicot N, Philippidou D, Vallar L, Kreis S. Interplay of microRNAs, transcription factors and target genes: linking dynamic expression changes to function. Nucleic Acids Res. 2013;41(5):2817\u201331.","journal-title":"Nucleic Acids Res"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01164-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-025-01164-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01164-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:57:30Z","timestamp":1774943850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-025-01164-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1164"],"URL":"https:\/\/doi.org\/10.1186\/s13020-025-01164-4","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The National Natural Science Foundation of China grant number has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The collection of clinical specimens was approved by the Ethics Committee of Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (Approval No. 2018-K-12). The animal experiment was approved by the Animal Ethics Committee of Shanghai University of Traditional Chinese Medicine (PZSHUTCM2501060003).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The data presented in this manuscript have not been submitted or published elsewhere. All authors agree to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}